Overview
Large B-cell lymphoma with IRF4 rearrangement is a rare subtype characterized by a specific chromosomal rearrangement involving the IRF4 gene, leading to its aberrant expression and potentially influencing clinical behavior and treatment response 1.Diagnosis
Genetic testing for IRF4 rearrangement via cytogenetic analysis or next-generation sequencing is essential 1.
Morphological and immunophenotypic evaluation to confirm large B-cell lymphoma characteristics 1.
No specific grading system uniquely tailored for IRF4 rearranged cases; standard lymphoma grading applies 1.Management
First-line treatment typically follows standard aggressive B-cell lymphoma protocols, often including anthracycline-based chemotherapy regimens such as R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) 1.
Adjunctive rituximab is recommended for its anti-CD20 activity, enhancing response rates 1.
Specific dose adjustments or alternative regimens for IRF4 rearranged cases are not well-defined in current guidelines 1.Special Populations
Limited evidence specific to pregnancy, pediatrics, elderly, or comorbidities in IRF4 rearranged large B-cell lymphoma; management generally follows standard lymphoma guidelines with caution 1.Key Recommendations
Confirm diagnosis through genetic testing for IRF4 rearrangement 1 (Evidence: Expert opinion).
Initiate treatment with standard aggressive B-cell lymphoma protocols, such as R-CHOP 1 (Evidence: Expert opinion).
Monitor and manage comorbidities according to standard lymphoma care guidelines, with individualized adjustments as necessary 1 (Evidence: Expert opinion).References
1 Vitry A, Lexchin J, Sasich L, Dupin-Spriet T, Reed T, Bertele V et al.. Provision of information on regulatory authorities' websites. Internal medicine journal 2008. link